Apellis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Apellis Pharmaceuticals
APLS Stock  USD 20.95  1.01  5.07%   
Apellis Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apellis Pharmaceuticals' valuation are provided below:
Gross Profit
605 M
Profit Margin
0.0443
Market Capitalization
2.6 B
Enterprise Value Revenue
2.4785
Revenue
1 B
There are over one hundred nineteen available fundamental signals for Apellis Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Apellis Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Apellis Pharmaceuticals Total Revenue

943.5 Million

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 48.8 M or Selling General Administrative of 504.4 M, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 16.25. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Apellis Stock
Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1 B425.8 M
Slightly volatile
Other Current Liabilities169.3 M161.2 M64.2 M
Slightly volatile
Total Current Liabilities224 M213.3 M82.2 M
Slightly volatile
Total Stockholder Equity276 M262.8 M115.8 M
Slightly volatile
Property Plant And Equipment Net16.2 M21.9 M10.2 M
Slightly volatile
Accounts Payable46.6 M44.4 M15.2 M
Slightly volatile
Cash302.8 M473 M240.8 M
Slightly volatile
Non Current Assets Total116 M110.5 M29.7 M
Slightly volatile
Cash And Short Term Investments337.5 M478.6 M265.4 M
Slightly volatile
Net Receivables328.1 M312.5 M74.3 M
Slightly volatile
Common Stock Total Equity9.7 K9.2 K4.9 K
Slightly volatile
Common Stock Shares Outstanding149.6 M142.5 M59 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1 B425.8 M
Slightly volatile
Inventory53.3 M94.9 M28.7 M
Slightly volatile
Other Current Assets22 M21.4 M16.7 M
Slightly volatile
Other Stockholder Equity3.9 B3.8 B1.2 B
Slightly volatile
Total Liabilities792.7 M755 M310 M
Slightly volatile
Property Plant And Equipment Gross18.1 M21.9 M13.8 M
Slightly volatile
Total Current Assets952.7 M907.3 M396.1 M
Slightly volatile
Common Stock14.5 K13.8 K6.2 K
Slightly volatile
Other Assets19.1 M18.2 M8 M
Slightly volatile
Property Plant Equipment16.9 M28.6 M11.2 M
Slightly volatile
Capital Surpluse743.6 M708.2 M358 M
Slightly volatile
Preferred Stock Total Equity93.1 M105.9 M87.7 M
Slightly volatile
Short and Long Term Debt Total567.3 M540.3 M176.2 M
Slightly volatile
Other Liabilities192.4 M363 M131.7 M
Slightly volatile
Long Term Debt546.8 M520.8 M154.9 M
Slightly volatile
Long Term Debt Total172.1 M164 M84 M
Slightly volatile
Net Invested Capital822.8 M783.6 M326.8 M
Slightly volatile
Short and Long Term Debt1.4 M1.5 M13.3 M
Slightly volatile
Net Working Capital525.7 M694 M368.9 M
Slightly volatile
Short Term Debt5.7 M6.1 M14.9 M
Slightly volatile
Capital Stock10.2 K13.8 K7.9 K
Slightly volatile
Capital Lease Obligations20.1 M19.5 M16.4 M
Slightly volatile
Current Deferred Revenue86.1 M92.9 M107.2 M
Slightly volatile
Short Term Investments4.1 M4.4 M206.6 M
Slightly volatile
Non Current Liabilities Other6.8 M7.2 M277.7 M
Slightly volatile

Apellis Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.5 M1.6 M12.9 M
Very volatile
Selling General Administrative504.4 M480.4 M154 M
Slightly volatile
Other Operating Expenses1.1 B1.1 B376.3 M
Slightly volatile
Research Development202 M376.7 M164.1 M
Slightly volatile
Total Operating Expenses1 B952.9 M345.9 M
Slightly volatile
Non Recurring21.2 M23.8 M26 M
Slightly volatile
Interest Income7.6 M14.7 M4.7 M
Slightly volatile
Reconciled Depreciation1.2 M2.1 M642.1 K
Slightly volatile
Tax Provision1.4 M1.3 M1.6 M
Slightly volatile
Selling And Marketing Expenses100.6 M95.8 M17.9 M
Slightly volatile

Apellis Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation137.8 M131.2 M43.2 M
Slightly volatile
Begin Period Cash Flow265.7 M405.1 M210.1 M
Slightly volatile
Depreciation2.2 M2.1 M747.4 K
Slightly volatile
Other Non Cash Items24.9 M14.3 M18.4 M
Slightly volatile
Total Cash From Financing Activities256.1 M171.6 M190.8 M
Slightly volatile
End Period Cash Flow303.4 M474.5 M241.3 M
Slightly volatile
Change To Netincome183.7 M174.9 M77.7 M
Slightly volatile
Dividends Paid258.3 M290.6 M317.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.535.8220.9249
Very volatile
PTB Ratio16.2515.5718.7149
Slightly volatile
Days Sales Outstanding18314689.5644
Slightly volatile
Book Value Per Share1.541.661.7145
Slightly volatile
Average Payables3.4 M6.3 M4.6 M
Slightly volatile
Stock Based Compensation To Revenue0.160.170.2943
Pretty Stable
Capex To Depreciation0.250.262.2701
Slightly volatile
PB Ratio16.2515.5718.7149
Slightly volatile
EV To Sales5.615.9119.6958
Very volatile
Inventory Turnover1.351.280.419
Slightly volatile
Days Of Inventory On Hand2792941.6 K
Pretty Stable
Payables Turnover3.233.517.4769
Slightly volatile
Sales General And Administrative To Revenue0.580.610.908
Slightly volatile
Average Inventory192 K216 K235.8 K
Slightly volatile
Research And Ddevelopement To Revenue0.460.481.5807
Pretty Stable
Capex To Revenue6.0E-46.0E-40.0164
Slightly volatile
Cash Per Share3.383.023.5417
Slightly volatile
Days Payables Outstanding131138573
Pretty Stable
Income Quality0.860.510.7851
Pretty Stable
Current Ratio4.654.898.4216
Slightly volatile
Tangible Book Value Per Share1.541.661.7145
Slightly volatile
Receivables Turnover5.593.317.916
Slightly volatile
Shareholders Equity Per Share1.541.661.7145
Slightly volatile
Debt To Equity1.111.850.9016
Slightly volatile
Capex Per Share0.00360.00370.0152
Pretty Stable
Revenue Per Share5.965.683.4982
Slightly volatile
Interest Debt Per Share1.863.711.7444
Slightly volatile
Debt To Assets0.50.480.2428
Slightly volatile
Operating Cycle418440615
Slightly volatile
Price Book Value Ratio16.2515.5718.7149
Slightly volatile
Days Of Payables Outstanding131138573
Pretty Stable
Ebt Per Ebit0.891.071.073
Slightly volatile
Company Equity Multiplier2.663.492.91
Slightly volatile
Long Term Debt To Capitalization0.350.60.3272
Slightly volatile
Total Debt To Capitalization0.370.610.338
Slightly volatile
Debt Equity Ratio1.111.850.9016
Slightly volatile
Quick Ratio4.164.388.1344
Slightly volatile
Net Income Per E B T0.80.910.9739
Pretty Stable
Cash Ratio2.422.557.2038
Slightly volatile
Days Of Inventory Outstanding2792941.6 K
Pretty Stable
Days Of Sales Outstanding18314689.5644
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.161.0215
Slightly volatile
Price To Book Ratio16.2515.5718.7149
Slightly volatile
Fixed Asset Turnover38.7936.9414.9176
Slightly volatile
Debt Ratio0.50.480.2428
Slightly volatile
Price Sales Ratio5.535.8220.9249
Very volatile
Asset Turnover0.830.790.3559
Slightly volatile
Gross Profit Margin0.980.84930.9064
Slightly volatile
Price Fair Value16.2515.5718.7149
Slightly volatile

Apellis Fundamental Market Drivers

Forward Price Earnings46.2963
Cash And Short Term Investments416.1 M

Apellis Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue92.9 M86.1 M
Total Revenue898.6 M943.5 M
Cost Of Revenue135.4 M142.2 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 0.61  0.58 
Research And Ddevelopement To Revenue 0.48  0.46 
Revenue Per Share 5.68  5.96 
Ebit Per Revenue(0.19)(0.20)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY